Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $15.00.
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Indivior Announces Q3 2024 Financial Results